Magazine article Clinical Psychiatry News

Aripiprazole May Prevent Manic Relapse in Bipolar Disorder

Magazine article Clinical Psychiatry News

Aripiprazole May Prevent Manic Relapse in Bipolar Disorder

Article excerpt

VIENNA -- The atypical antipsychotic aripipra-zole demonstrated sustained long-term efficacy for prevention of manic relapse in patients with bipolar disorder, Dr. Roger S. McIntyre reported at the annual congress of the European College of Neuropsychopharmacology.

This 100-week, placebo-controlled trial was particularly noteworthy because it was the first 2-year study of a maintenance therapy in bipolar disorder since a lithium study published more than 30 years ago. The data provide strong support for aripipra-zole (Abilify) as a safe and effective long-term mood-stabilizing agent in patients with a recent manic or mixed episode, said Dr. McIntyre of the University of Toronto.

The study began with a stabilization phase involving 567 bipolar disorder patients with a recent manic or mixed episode who received open-label aripiprazole at 15 or 30 mg/day for 6-18 weeks. The 161 subjects who achieved stabilization criteria--a Montgomery-Asberg Depression Rating Scale of 13 or less and a Young Mania Rating Scale of 10 or less for 6 consecutive weeks--were randomized to double-blind aripiprazole or placebo for 26 weeks. …

Search by... Author
Show... All Results Primary Sources Peer-reviewed

Oops!

An unknown error has occurred. Please click the button below to reload the page. If the problem persists, please try again in a little while.